Review
Endocrinology & Metabolism
Chengxia Kan, Yang Zhang, Fang Han, Qian Xu, Tongtong Ye, Ningning Hou, Xiaodong Sun
Summary: The systematic review and meta-analysis found that metformin and sulfonylurea use were associated with lower mortality risk in patients with type 2 diabetes who have COVID-19, while insulin use was linked to higher mortality. There was no significant difference in mortality between DPP-4 inhibitor users and non-users, indicating a need for further exploration of the effects of antidiabetic agents in this population.
FRONTIERS IN ENDOCRINOLOGY
(2021)
Article
Endocrinology & Metabolism
Nam Nhat Nguyen, Dung Si Ho, Hung Song Nguyen, Dang Khanh Ngan Ho, Hung-Yuan Li, Chia-Yuan Lin, Hsiao-Yean Chiu, Yang-Ching Chen
Summary: This study compared the effects of preadmission use of antidiabetic medications on in-hospital mortality in patients with COVID-19 and type 2 diabetes. The findings showed that metformin, glucagon-like peptide-1 receptor agonist (GLP-1RA), and sodium-glucose transporter-2 inhibitor (SGLT-2i) were associated with lower mortality rates, while dipeptidyl peptidase-4 inhibitor (DPP-4i) and insulin were linked to increased mortality. Other antidiabetic medications had no significant effect on mortality rates.
METABOLISM-CLINICAL AND EXPERIMENTAL
(2022)
Review
Public, Environmental & Occupational Health
Chenyang Zhang, Huaqing Jin, Yi Feng Wen, Guosheng Yin
Summary: This network meta-analysis evaluated the efficacy of various treatments for COVID-19 compared to standard care, showing superiority in terms of mortality, mechanical ventilation, hospital discharge, and viral clearance. Tocilizumab was found to be particularly effective in preventing severe outcomes and increasing discharge rates. Additionally, the study highlighted the clinical efficacy of antineoplastic agents, immunostimulants, and immunosuppressants in reducing mortality, ventilation risk, and increasing discharge rates, providing valuable information for potential COVID-19 treatments.
FRONTIERS IN PUBLIC HEALTH
(2021)
Article
Multidisciplinary Sciences
David McConnell, Marie Harte, Cathal Walsh, Desmond Murphy, Alistair Nichol, Michael Barry, Roisin Adams
Summary: This study aimed to evaluate the effectiveness of neutralising monoclonal antibody (nMAB) therapies in individuals at high risk of severe COVID-19. The results showed that nMABs can reduce hospitalisation and potentially lower the risks of mortality, ICU admission, and invasive ventilation, although the exact effects are uncertain due to limited data and the emergence of resistant variants.
SCIENTIFIC REPORTS
(2022)
Article
Endocrinology & Metabolism
Razieh Bidhendi Yarandi, Mina Amiri, Fahimeh Ramezani Tehrani, Samira Behboudi-Gandevani
Summary: This study evaluated the methodological quality of existing meta-analyses on antidiabetic agents for gestational diabetes mellitus. It found that metformin may be the best treatment option for most adverse neonatal outcomes, while glyburide is most effective in reducing the risk of adverse maternal outcomes in gestational diabetes mellitus patients. The results highlight the need for more high-quality studies to update and confirm these findings.
JOURNAL OF DIABETES INVESTIGATION
(2021)
Article
Multidisciplinary Sciences
Elisa Ferrari, Luna Gargani, Greta Barbieri, Lorenzo Ghiadoni, Francesco Faita, Davide Bacciu
Summary: We propose a clinical data analysis workflow based on Bayesian Structure Learning (BSL). This workflow incorporates prior medical knowledge into the learning process and provides explainable results in the form of causal connections among analyzed features. Evaluation on a COVID-19 dataset shows that the proposed framework gives a schematic overview of the multi-factorial processes contributing to the outcome and rediscovers established cause-effect relationships. Furthermore, the approach yields a highly interpretable tool that accurately predicts the outcome using a small number of features.
Article
Endocrinology & Metabolism
Yiru Chen, Xiuneng Li, Yu Dai, Jingjing Zhang
Summary: There is an association between abnormal thyroid-related hormones in COVID-19 patients and the severity of the disease and mortality.
FRONTIERS IN ENDOCRINOLOGY
(2022)
Review
Multidisciplinary Sciences
Krisztina Toth, Stefano Fresilli, Nicola Paoli, Giacomo Maiucci, Mariateresa Salvioni, Yuki Kotani, Stephan Katzenschlager, Markus A. Weigand, Giovanni Landoni
Summary: There is no significant difference in D-dimer levels between non-COVID-19 ARDS and COVID-19 ARDS patients, but the length of hospital stay is shorter in non-COVID-19 ARDS patients.
Article
Computer Science, Interdisciplinary Applications
Enrico Longato, Mario Luca Morieri, Giovanni Sparacino, Barbara Di Camillo, Annamaria Cattelan, Sara Lo Menzo, Marco Trevenzoli, Andrea Vianello, Gabriella Guarnieri, Federico Lionello, Angelo Avogaro, Paola Fioretto, Roberto Vettor, Gian Paolo Fadini
Summary: This study utilizes dynamic Bayesian networks and prototyping to integrate data analysis, allowing for the visualization of patient trajectories in COVID-19 outcomes, which could guide timely and appropriate clinical decisions.
COMPUTER METHODS AND PROGRAMS IN BIOMEDICINE
(2022)
Review
Endocrinology & Metabolism
Sai Tian, Jiaxuan Jiang, Jin Wang, Zhou Zhang, Yingwen Miao, Xinlu Ji, Yan Bi
Summary: This study aimed to summarise the current evidence on different antidiabetic drugs for delaying cognitive impairment in patients with type 2 diabetes mellitus. The findings showed that SGLT-2i, GLP-1RA, thiazolidinedione, and DPP-4i were associated with a decreased risk of dementia, while sulfonylurea increased the risk. Network meta-analysis showed that SGLT-2i was the most effective in reducing dementia outcomes. These findings provide valuable evidence for clinical practice.
DIABETES-METABOLISM RESEARCH AND REVIEWS
(2023)
Article
Cardiac & Cardiovascular Systems
Ramesh Nadarajah, Jianhua Wu, Ben Hurdus, Samira Asma, Deepak L. Bhatt, Giuseppe Biondi-Zoccai, Laxmi S. Mehta, C. Venkata S. Ram, Antonio Luiz P. Ribeiro, Harriette G. C. Van Spall, John E. Deanfield, Thomas F. Luscher, Mamas Mamas, Chris P. Gale
Summary: The COVID-19 pandemic had a significant impact on care and outcomes of non-COVID-19 cardiovascular diseases, with varying severity based on country income classification.
EUROPEAN HEART JOURNAL
(2022)
Article
Endocrinology & Metabolism
Yan Yang, Zixin Cai, Jingjing Zhang
Summary: Insulin treatment may increase mortality and incidence of severe/critical complications in patients with COVID-19 and diabetes, while showing a mixed effect on in-hospital admission. Additional large-scale studies are required to confirm these findings and explore the underlying mechanisms.
FRONTIERS IN ENDOCRINOLOGY
(2021)
Review
Infectious Diseases
Luis Ayerbe, Carlos Risco-Risco, Ivo Forgnone, Maria Perez-Pinar, Salma Ayis
Summary: This systematic review and meta-analysis found no evidence to support the use of azithromycin in the treatment of COVID-19. Future research should focus on other drugs for the management of COVID-19 patients.
JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY
(2022)
Review
Medicine, General & Internal
Daniel D'Souza, Jessica Empringham, Petros Pechlivanoglou, Elizabeth M. Uleryk, Eyal Cohen, Rayzel Shulman
Summary: This systematic review and meta-analysis found higher incidence rates of type 1 diabetes and diabetic ketoacidosis among children and adolescents during the COVID-19 pandemic compared with before the pandemic. The findings suggest the need for further research to understand the underlying mechanisms and provide adequate resources and support for this population.
Review
Infectious Diseases
Hideto Yasuda, Takuya Mayumi, Hiromu Okano
Summary: This study used a network meta-analysis to examine the effects of different anticoagulant doses in patients with COVID-19. The results showed that both prophylactic and treatment doses were associated with a lower risk of short-term mortality compared to no treatment in patients with moderate COVID-19. However, there was no significant difference between the prophylactic and treatment dose groups. For patients with severe COVID-19, the absence of trials with a no-treatment group prevented a network meta-analysis, but pairwise comparison showed no significant difference between the prophylactic and treatment dose groups. Therefore, the treatment dose is preferred for both moderate and severe COVID-19 patients.